Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel B Walter

Showing results (111-120 of 139) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|May 27, 2021
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsRobert W Frenck, Nicola P Klein, Nicholas Kitchin, et al.
Vaccine|March 19, 2025
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of ageTheresa E Hegmann, Emmanuel B Walter, Michael J Smith, et al.
Annals of Internal Medicine|January 17, 2022
Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021Isaac See, Allison Lale, Paige Marquez, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 seasonJessie R Chung, Ashley M Price, Stacey L House, et al.
The Journal of Infectious Diseases|June 8, 2026
Birth cohort effects in adults associated with influenza A(H1N1)pdm09 vaccine effectivenessFeng Liu, F Liaini Gross, Zhunan Li, et al.
Cell Host & Microbe|July 2, 2014
Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangementsKatherine J L Jackson, Yi Liu, Krishna M Roskin, et al.
Journal of the Pediatric Infectious Diseases Society|June 11, 2024
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-OldsLawrence D Sher, Justice K Boakye-Appiah, Sungeen Hill, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2024
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US AdultsChristina A Rostad, Robert L Atmar, Emmanuel B Walter, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Pageof 14

Showing results (111-120 of 139) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|May 27, 2021
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsRobert W Frenck, Nicola P Klein, Nicholas Kitchin, et al.
Vaccine|March 19, 2025
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of ageTheresa E Hegmann, Emmanuel B Walter, Michael J Smith, et al.
Annals of Internal Medicine|January 17, 2022
Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021Isaac See, Allison Lale, Paige Marquez, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 seasonJessie R Chung, Ashley M Price, Stacey L House, et al.
The Journal of Infectious Diseases|June 8, 2026
Birth cohort effects in adults associated with influenza A(H1N1)pdm09 vaccine effectivenessFeng Liu, F Liaini Gross, Zhunan Li, et al.
Cell Host & Microbe|July 2, 2014
Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangementsKatherine J L Jackson, Yi Liu, Krishna M Roskin, et al.
Journal of the Pediatric Infectious Diseases Society|June 11, 2024
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-OldsLawrence D Sher, Justice K Boakye-Appiah, Sungeen Hill, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2024
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US AdultsChristina A Rostad, Robert L Atmar, Emmanuel B Walter, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Pageof 14